Clinical trials
Nasopharyngeal Cancinoma (NPC) clinical trials
Below are recruiting nasopharyngeal cancinoma (npc) clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06669611RecruitingPhase 3
Comparing two drug combos for advanced nasopharyngeal cancer
This trial tests whether a new drug combination (Nab-Paclitaxel with Camrelizumab) works better than the standard GP chemotherapy plus Camrelizumab for people whose nasopharyngeal cancer has come back or spread. The goal is to find a more effective treatment option.
Guangzhou, GuangdongAges 18 years+ - NCT07311772RecruitingPhase 3
Testing houyanqing liquid for mouth sores during radiation
This trial tests a liquid medicine (houyanqing) to prevent or treat mouth sores caused by radiation therapy for nasopharyngeal cancer. You swish it in your mouth during radiation to see if it helps reduce pain and healing time.
Beijing, Beijing MunicipalityAges 18–75 - NCT07154069RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer after chemo
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Guangzhou, GuangdongAges 18–65 - NCT07528183RecruitingPhase 2
Immunotherapy after chemo and radiation for recurrent nose cancer
This trial tests whether maintenance immunotherapy (PD-1 inhibitor) followed by delayed salvage radiation therapy can help keep your cancer under control after you have already responded to initial chemo-immunotherapy. It is for people with recurrent nasopharyngeal carcinoma that has come back in the nose or neck area, but has not spread to distant organs.
Fuzhou, FujianAges 18–70 - NCT07232680Recruiting
Immune profile study for nasopharyngeal cancer patients
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
Taoyuan City, TaiwanAges 18 years+ - NCT07705243RecruitingPhase 3
Maintenance therapy for advanced nasopharyngeal cancer
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
Guangzhou, GuangdongAges 18–75 - NCT07013461Recruiting
Nasopharyngeal cancer staging study
This study looks at how well the current cancer staging system works for nasopharyngeal cancer. If you have been diagnosed with this type of cancer between October 2025 and September 2026, you may be able to join.
Shenzhen, GuangdongAges 18 years+ - NCT06846450RecruitingPhase 3
Comparing radiation types for nasopharyngeal cancer
This trial compares two types of radiation therapy (IMRT or IMPT plus CIRT) to see which works better for patients with nasopharyngeal cancer that hasn't spread. It's for people who have not had radiation to the head or neck before.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06912698RecruitingPhase 3
Lower vs. standard radiation for early nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
Guangzhou, GuangdongAges 18–70 - NCT06788002RecruitingPhase 2
Low-dose radiation and chemoimmunotherapy for NPC with liver spread
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
Changsha, HunanAges 18–70 - NCT06749899RecruitingPhase 3
Immunotherapy with chemoradiation for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Fuzhou, FujianAges 18–65 - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06829147Recruiting
AI to diagnose lymph node spread in nasopharyngeal cancer
This trial tests whether a computer model can accurately detect if cancer has spread to lymph nodes in patients with nasopharyngeal carcinoma. It uses MRI and PET/CT scans taken before treatment to see if the AI can replace or supplement current methods.
Guangzhou, GuangdongAges Any age - NCT07325539RecruitingPhase 2
Radiation and immunotherapy with chemo for nose and throat cancer
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–65 - NCT07362979RecruitingPhase 2
Toripalimab with chemo for advanced nasopharyngeal cancer
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
Dongguan, GuangdongAges 18–70 - NCT06676722RecruitingPhase 2
SBRT and two targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
Xiamen, FujianAges 18–75 - NCT07376603Recruiting
Radiation therapy alone for early-stage nasopharyngeal cancer
This trial tests whether intense radiation therapy (IMRT) alone is effective for people with stage IB nasopharyngeal carcinoma (a type of head and neck cancer) that has not spread to lower lymph nodes or formed large, matted nodes. If you qualify, you would receive targeted radiation without chemotherapy.
Fuzhou, FujianAges 18–70 - NCT06831357Recruiting
Predicting Cancer Spread in Nasopharyngeal Cancer Using AI
This trial uses a deep learning computer model to look at tissue images and MRI scans to predict whether nasopharyngeal carcinoma may spread to other parts of the body. It may help doctors decide on the best treatment for people with certain stages of this cancer.
Guangzhou, GuangdongAges Any age - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT07496190RecruitingPhase 2
Becotatug Vedotin for advanced nasopharyngeal cancer not responding well to initial treatment
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
Guangzhou, GuangdongAges 18–70 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT07625423RecruitingPhase 1
Gene therapy injection for advanced head and neck cancer
This trial tests a new treatment where a specially designed virus carrying an anti-cancer gene is injected directly into tumors in the head and neck area. It's for patients whose cancer has come back or spread after prior chemotherapy and who cannot have surgery or radiation.
Chengdu, ChinaAges 18–65
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nasopharyngeal cancinoma (npc)?
- Yes. Clin2 currently lists 22 recruiting nasopharyngeal cancinoma (npc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nasopharyngeal cancinoma (npc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nasopharyngeal cancinoma (npc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.